الفهرس 
Introduction and aim of the workOnly 14 pages are availabe for public view
 |  | from | 169 |  |  |
| | | from | 169 | | |
Abstract
This study aimed to : Acute myeloid leukemia (AML) is malignant disease of the bone marrow characterized by clonal proliferation of immature hematopoietic progenitors with myeloid differentiation (myeloblasts) in the BM, peripheral blood or extramedullary tissues.
Current management of AML includes induction chemotherapy followed by several courses of consolidation chemotherapy or allogeneic HSCT. Patients with significant co-morbidity and the elderly are often not eligible for intensive treatment. They should receive BSC or palliative systemic treatment, which may incorporate either LDAC or a demethylating agent; decitabine or azacytidine.
The current standard chemotherapy is troubled by both low survival rates and deaths due to toxicity. Molecular abnormalities identified many cellular pathways that contribute to leukemogenesis which led to development of novel therapies.
Novel therapy for AML should improve remission rates, survival with better tolerability, improved quality of life and minimize utilization of health care resources. The most studied are: Gemtuzumab, Tyrosine kinase inhibitors, DNAMT inhibitors, Histone deacetylase inhibitors, Clofarabine and Bortezomib.